Given all the Zantac shenanigans, sort of nice to see US markets down and GSK up 8% ;-) |
I have some GSK, I don't follow them at all tbh, so I found his post useful. |
Don't knock T M he's reliable and consistent unlike many others who talk their own book only. |
As usual all the misogynists gave fallen silent on good results. Well done Emma. Diversification strategy and the zantac bullet bitten together with a helluva pipeline. Apart from the nutcases over the pond whats not to like. |
U.K. stocks still seeing investor outflows in Jan .. GSK should help buck that trend, excellent outlook and kitchen sinked the zantac issue so all to play for here |
Think its for those to lazy to look at rns |
Share buyback should lend good support and will be buying stock at a low valuation, so the sooner they start the better |
Share price is range bound, gone nowhere for decades. |
Trader
Why do you repeat that which is already in the public domain? |
GSK delivers strong 2024 performance with further improvement to long-term growth outlook
Strong sales and Core EPS growth reflecting accelerating momentum in Specialty Medicines offsetting lower Vaccine sales
•
Total 2024 sales £31.4 billion +3% AER; +7% CER
•
Specialty Medicines sales +19%. HIV sales +13%. Oncology +98%. Respiratory/Immunology and Other +13%
•
Vaccines sales -4%. Shingrix +1% and Arexvy -51%
•
General Medicines sales +6%. Trelegy +27%
•
Total operating profit -33% and Total EPS -40% largely driven by £1.8 billion ($2.3 billion) charge relating to settlement of Zantac litigation
•
Core operating profit +11% (with further positive impact of +2% ex COVID) and Core EPS +10% (with further positive impact of +2% ex COVID) reflecting strong Specialty Medicines performance and disciplined increased investment in progressing the R&D portfolio
•
Cash generated from operations in the year of £8 billion with Free cash flow of £3 billion |
It's the pipeline-for the first time in years GSK has one. |
No thanks. Keep it British |
Now's the time if there are any predators looking for a cheap acquisition. |
Errr funny enough market doesn't seem to agree with you - I will take their opinion |
#Gary Cook, this could indeed be the set of catalysts that reverse the share price trend for us longer term, 2000 pence for FY-2025 sounds a mile off today but these things can happen.. :o)
Sales and profit growth
Growth in dividends
GBP 2BN of share buybacks over 18 months |
Bit of a relief for me after the clanger of VOD yesterday |
Bring it on 1,500p,1,600p,1,700p,and 1,800p.Could we see 2000p by year end. Possible ! |
Which is good for a pharma and its rising |
Big thumbs up from the market, mind the gap.. :o)
Worth waiting for, but it was painful watching the slide from 1800-1300 over 2024.. |
Well, happy enough with those results and glad I added quite a few of this oversold share. The increase in dividend is nice, however at current share price represents a yield of 'only' 4%. |
GSK delivers strong 2024 performance with further improvement to long-term growth outlook
Strong sales and Core EPS growth reflecting accelerating momentum in Specialty Medicines offsetting lower Vaccine sales
•
Total 2024 sales £31.4 billion +3% AER; +7% CER
•
Specialty Medicines sales +19%. HIV sales +13%. Oncology +98%. Respiratory/Immunology and Other +13%
•
Vaccines sales -4%. Shingrix +1% and Arexvy -51%
•
General Medicines sales +6%. Trelegy +27%
•
Total operating profit -33% and Total EPS -40% largely driven by £1.8 billion ($2.3 billion) charge relating to settlement of Zantac litigation
•
Core operating profit +11% (with further positive impact of +2% ex COVID) and Core EPS +10% (with further positive impact of +2% ex COVID) reflecting strong Specialty Medicines performance and disciplined increased investment in progressing the R&D portfolio
•
Cash generated from operations in the year of £8 billion with Free cash flow of £3 billion |
Nobody who has been watching GSK should be surprised at the beat. Too many brokers myopic obsession with current vaccine sales have made this stock a bargain |
GSK: GSK forecast sales in 2025 to grow 3%-5% and reported better-than-expected fourth-quarter earnings, as strength in its HIV and oncology portfolio offset weakness in its vaccines division. |
Register to chat with like-minded investors on our interactive forums.
Hot Features
Premium
